Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

Myelosuppression by sunitinib is flt-3 genotype dependent

(2010) N P van Erp et al.   BRITISH JOURNAL OF CANCER

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) R. J. Amato et al.   CLINICAL CANCER RESEARCH

Targeting immune suppressing myeloid-derived suppressor cells in oncology

(2010) Johnny Kao et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine

(2010) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma Model

(2010) Zhuoshun Yang et al.   PLoS One

The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

(2009) Ingrid M. E. Desar et al.   ACTA ONCOLOGICA

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

(2009) Joshua Ö. Haznedar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vaccination strategies in patients with renal cell carcinoma

(2009) Anne Marie Asemissen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations

(2009) Amanda L. Boehm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice

(2009) Yanhong Gu et al.   CLINICAL IMMUNOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

(2009) S. Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

(2007) Naeem Bhojani et al.   EUROPEAN UROLOGY